SCHEMBL5340249

SCHEMBL5340249

C=CC(=O)OC(=O)c1cccnc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.57
KMT2A Q03164 8/20 0.50
KDM4E B2RXH2 2/20 0.50
APP P05067 1/20 0.50
GAA P10253 1/20 0.50
HCAR3 P49019 1/20 0.50
HCAR2 Q8TDS4 1/20 0.50
MAPT P10636 1/20 0.50
LMNA P02545 3/20 0.49
ATM Q13315 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
F7 P08709 1/20 0.49
F3 P13726 1/20 0.49
SARM1 Q6SZW1 1/20 0.49
SIRT2 Q8IXJ6 1/20 0.49
SIRT6 Q8N6T7 1/20 0.49
SIRT1 Q96EB6 1/20 0.49
SIRT3 Q9NTG7 1/20 0.49
SIRT5 Q9NXA8 1/20 0.49
SIRT4 Q9Y6E7 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31648307 0.84 ALDH1A1 (0.71) ALDH1A1KMT2AKDM4EAPPGAA
SCHEMBL2491556 0.84 ALDH1A1 (0.71) ALDH1A1KMT2AKDM4EAPPGAA
SCHEMBL30659698 0.84 ALDH1A1 (0.71) ALDH1A1KMT2AKDM4EAPPGAA
SCHEMBL4641797 0.83 ALDH1A1 (0.62) ALDH1A1KMT2AKDM4EAPPGAA
SCHEMBL27893145 0.82 ALDH1A1 (0.69) ALDH1A1KMT2AKDM4EAPPGAA
SCHEMBL27673236 0.82 ALDH1A1 (0.69) ALDH1A1KMT2AKDM4EAPPGAA
Ammonia Solution, Strong SCHEMBL28264184 0.82 ALDH1A1 (0.69) ALDH1A1KMT2AKDM4EAPPGAA
SCHEMBL11524023 0.81 L3MBTL1 (0.61) ALDH1A1KMT2AKDM4EGAAMAPT
SCHEMBL4644655 0.81 ALDH1A1 (0.62) ALDH1A1KMT2AKDM4EAPPGAA
SCHEMBL10603067 0.80 ALDH1A1 (0.67) ALDH1A1KMT2AKDM4EAPPGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7312334-B2 Method of preparing inhibitors phosphodiesterase-4 MERCK & CO. INC. (US) 2007-12-25 US disclosed
CN-1326856-C Method of preparing inhibitors of phosphodiesterase-4 MERCK & CO INC (US) 2007-07-18 CN disclosed
CN-1738818-A Process for preparing phosphodiesterase-4 inhibitors MERCK & CO INC (US) 2006-02-22 CN disclosed
US-20060019981-A1 Method of preparing inhibitors phosphodiesterase-4 MERCK & CO., INC. 2006-01-26 US disclosed
EP-1397359-B1 1-BIARYL-1,8-NAPTHYRIDIN-4-ONE PHOSPHODIESTERASE-4 INHIBITORS MERCK FROSST CANADA INC (CA) 2005-08-31 EP disclosed
EP-1565466-A2 METHOD OF PREPARING INHIBITORS OF PHOSPHODIESTERASE-4 Merck & Co., Inc. (US) 2005-08-24 EP disclosed
US-6909002-B2 Method of preparing inhibitors of phosphodiesterase-4 MERCK & CO., INC. (US) 2005-06-21 US disclosed
WO-2004048377-A2 METHOD OF PREPARING INHIBITORS OF PHOSPHODIESTERASE-4 MERCK & CO., INC. (US) 2004-06-10 WO disclosed
US-20040102472-A1 Method of preparing inhibitors of phosphodiesterase-4 MERCK & CO., INC. 2004-05-27 US disclosed
EP-1397359-A1 1-BIARYL-1,8-NAPTHYRIDIN-4-ONE PHOSPHODIESTERASE-4 INHIBITORS Merck Frosst Canada & Co. (CA) 2004-03-17 EP disclosed
US-6677351-B2 USEFUL IN TREATMENT OF ASTHMA AND INFLAMMATION MERCK FROSST CANADA & CO. (CA) 2004-01-13 US disclosed
US-20030096829-A1 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors MERCK FROSST CANADA LTD. (CA) 2003-05-22 US disclosed
WO-2002094823-A1 1-BIARYL-1,8-NAPTHYRIDIN-4-ONE PHOSPHODIESTERASE-4 INHIBITORS MERCK FROSST CANADA & CO. (CA) 2002-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102472-A1 Method of preparing inhibitors of phosphodiesterase-4 PDE4B, PDE4A, PDE5A ALDH1A1 558/4885KMT2A 2291/4885KDM4E 467/4885
US-20030096829-A1 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors PDE4A, PDE4B, PDE7A ALDH1A1 314/4885KMT2A 2300/4885KDM4E 1159/4885
US-20060019981-A1 Method of preparing inhibitors phosphodiesterase-4 PDE4A, PDE5A, PDE3A ALDH1A1 572/4885KMT2A 2125/4885KDM4E 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.